Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis

Study acronym: GLUREDLUP
StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 1, 2022 to Mar 2, 2022
    v3
  2. Start date: Feb 1, 2022 to Mar 1, 2022v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the study is to evaluate the efficacy of a therapeutic regimen which decreases glucocorticoid exposure compared with standard therapy in patients with proliferative lupus nephritis during remission induction by evaluating the histological and clinical remission.
Trial Details
NCT Number NCT05207358
Lead Sponsor Institutul Clinic Fundeni
Conditions
(from sponsor)		 Lupus Nephritis
Related terms Lupus Nephritis
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov